Join Growin Stock Community!

Abpro corporationABP.US Overview

US StockHealthcare
(No presentation for ABP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABP AI Insights

ABP Overall Performance

ABP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABP Recent Performance

-

Abpro corporation

-3.61%

Avg of Sector

-2.16%

S&P500

ABP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABP Key Information

ABP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABP Profile

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Price of ABP

ABP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.93
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
102.80
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-7670.49%
Revenue Growth (YoY)
0.00%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.93
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
102.80
PB Ratio
-
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-7670.49%
Revenue Growth (YoY)
0.00%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ABP's latest earnings report released?

    The most recent financial report for Abpro corporation (ABP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABP's short-term business performance and financial health. For the latest updates on ABP's earnings releases, visit this page regularly.

  • How is ABP's revenue growth?

    In the latest financial report, Abpro corporation (ABP) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ABP have?

    At the end of the period, Abpro corporation (ABP) held Total Cash and Cash Equivalents of 343K, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ABP's EPS continuing to grow?

    According to the past four quarterly reports, Abpro corporation (ABP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABP?

    Abpro corporation (ABP)'s Free Cash Flow (FCF) for the period is -2.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 128.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABP?

    The latest valuation data shows Abpro corporation (ABP) has a Price-To-Earnings (PE) ratio of -0.68 and a Price/Earnings-To-Growth (PEG) ratio of 0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.